DOI QR코드

DOI QR Code

Type 2 Myocardial Infarction: Another Hidden Cause of Mortality During the COVID-19 Pandemic

  • Eun Jeong Cho (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital) ;
  • Kyeongmin Byeon (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital) ;
  • Young-Hoon Jeong (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital)
  • Received : 2023.11.05
  • Accepted : 2023.11.12
  • Published : 2023.12.01

Abstract

Keywords

References

  1. Alsaidan AA, Al-Kuraishy HM, Al-Gareeb AI, et al. The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. Immun Inflamm Dis 2023;11:e798. 
  2. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021;76:970-9.  https://doi.org/10.1136/thoraxjnl-2020-215383
  3. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461-7.  https://doi.org/10.1038/s41591-022-01840-0
  4. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237-69.  https://doi.org/10.1093/eurheartj/ehy462
  5. Glance LG, Joynt Maddox KE, Shang J, et al. The COVID-19 pandemic and associated inequities in acute myocardial infarction treatment and outcomes. JAMA Netw Open 2023;6:e2330327. 
  6. Thyagaturu H, Roma N, Angirekula A, et al. Trends and outcomes of type 2 myocardial infarction during the COVID-19 pandemic in the United States. Korean Circ J 2023;53:829-39.  https://doi.org/10.4070/kcj.2023.0063
  7. Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021;121:422-32.  https://doi.org/10.1055/s-0040-1718729
  8. Chaudhary R, Bliden KP, Kreutz RP, et al. Race-related disparities in COVID-19 thrombotic outcomes: beyond social and economic explanations. EClinicalMedicine 2020;29:100647. 
  9. Hayashi H, Izumiya Y, Fukuda D, et al. Real-world management of pharmacological thromboprophylactic strategies for COVID-19 patients in Japan: from the CLOT-COVID study. JACC Asia 2022;2:897-907.  https://doi.org/10.1016/j.jacasi.2022.09.005
  10. Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J 2021;51:202-21. https://doi.org/10.4070/kcj.2020.0537